Taiwan’s neurosurgery robotic surgical systems market is gradually gaining ground, driven by the growing demand for minimally invasive procedures, an ageing population, and rising chronic health conditions. Owing to these factors, the neurosurgery robotic surgical systems market is set to expand at a compound annual growth rate (CAGR) of 9 per cent through 2036, forecasts GlobalData.
GlobalData’s latest report, “Robotic Surgical Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036,” reveals that in 2024, Taiwan accounted for around 2 per cent of the neurosurgery robotic surgical systems market in the Asia-Pacific (APAC) region, primarily due to relatively lower domestic adoption compared to the larger regional markets.
Brain Navi Biotechnology, a Taiwan-based robotics firm, has recently secured FDA approval for its neurosurgical navigation robot, NaoTrac. The product has also previously received CE mark approval and clearance from Taiwan’s Food and Drug Administration (TFDA).
Shagufta Hasan, Medical Devices Analyst at GlobalData, states, “While Taiwan is gradually progressing in the field of neurosurgical robotics, limitations in regional hospital infrastructure and a shortage of specialised training programs continue to hinder widespread clinical adoption.”
To address the challenges and propel market advancement, it is essential to cultivate partnerships among the Taiwanese companies, hospitals, and research institutions. This collaboration will drive innovation and facilitate the adoption of new technologies. Additionally, investing in research and development is crucial for creating novel solutions. Advocacy for government initiatives and the procurement of funding are also key strategies to support and sustain growth in this sector.
Hasan concludes, “While Taiwan currently accounts for a smaller share of the APAC neurosurgical robotics market, regulatory progress, and localised innovations over the years signal steady momentum. As infrastructure strengthens and adoption grows, the market is expected to be better equipped to support precision care—gradually shaping Taiwan into a promising market.”